9,800 Shares in Alnylam Pharmaceuticals, Inc. (ALNY) Acquired by APG Asset Management N.V.
APG Asset Management N.V. purchased a new stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the 4th quarter, HoldingsChannel reports. The fund purchased 9,800 shares of the biopharmaceutical company’s stock, valued at approximately $1,037,000.
Other institutional investors have also recently bought and sold shares of the company. Strs Ohio acquired a new position in Alnylam Pharmaceuticals in the 4th quarter valued at approximately $141,000. CENTRAL TRUST Co raised its holdings in Alnylam Pharmaceuticals by 746.3% in the 4th quarter. CENTRAL TRUST Co now owns 1,134 shares of the biopharmaceutical company’s stock valued at $144,000 after acquiring an additional 1,000 shares in the last quarter. Livforsakringsbolaget Skandia Omsesidigt acquired a new position in Alnylam Pharmaceuticals in the 4th quarter valued at approximately $165,000. QS Investors LLC raised its holdings in Alnylam Pharmaceuticals by 59.7% in the 2nd quarter. QS Investors LLC now owns 2,408 shares of the biopharmaceutical company’s stock valued at $192,000 after acquiring an additional 900 shares in the last quarter. Finally, The Manufacturers Life Insurance Company raised its holdings in Alnylam Pharmaceuticals by 7.0% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 2,541 shares of the biopharmaceutical company’s stock valued at $203,000 after acquiring an additional 167 shares in the last quarter. 88.39% of the stock is owned by hedge funds and other institutional investors.
In related news, SVP Laurie Keating sold 30,000 shares of the firm’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $135.89, for a total transaction of $4,076,700.00. Following the completion of the sale, the senior vice president now directly owns 41,500 shares of the company’s stock, valued at approximately $5,639,435. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Michael Mason sold 36,745 shares of the firm’s stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $131.59, for a total value of $4,835,274.55. Following the sale, the vice president now directly owns 6,352 shares of the company’s stock, valued at $835,859.68. The disclosure for this sale can be found here. Insiders have sold a total of 220,409 shares of company stock valued at $28,667,017 over the last ninety days. Insiders own 4.30% of the company’s stock.
Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) opened at $116.32 on Friday. Alnylam Pharmaceuticals, Inc. has a twelve month low of $40.93 and a twelve month high of $147.63. The firm has a market capitalization of $11,440.00, a price-to-earnings ratio of -22.16 and a beta of 2.68. The company has a current ratio of 9.83, a quick ratio of 9.83 and a debt-to-equity ratio of 0.14.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 8th. The biopharmaceutical company reported ($1.48) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($1.03) by ($0.45). Alnylam Pharmaceuticals had a negative net margin of 664.70% and a negative return on equity of 46.94%. The business had revenue of $37.90 million for the quarter, compared to analyst estimates of $19.31 million. During the same period in the prior year, the business earned ($1.32) earnings per share. The company’s revenue for the quarter was up 116.6% on a year-over-year basis. equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -5.29 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: “9,800 Shares in Alnylam Pharmaceuticals, Inc. (ALNY) Acquired by APG Asset Management N.V.” was first reported by Daily Political and is the property of of Daily Political. If you are accessing this piece on another site, it was stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this piece can be viewed at https://www.dailypolitical.com/2018/02/09/9800-shares-in-alnylam-pharmaceuticals-inc-alny-acquired-by-apg-asset-management-n-v.html.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY).
Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.